Candid Health Raises $120M Series D — Autonomous RCM Gets Its Breakout Round

Candid Health just closed a $120 million Series D led by Sixth Street Growth, with existing backers Oak HC/FT, 8VC, and Y Combinator all returning. The round triples Candid's 2025 valuation — 18 months after their $52.5M Series C. Total raised is now past $219 million.

The number that earns the headline: annual recurring revenue grew 190% year over year. Net revenue retention is close to 200% — meaning existing customers almost never churn, and they keep spending more as their own claim volumes grow. Sixth Street interviewed nearly 40 Candid customers before writing the check. The feedback was, in their words, "consistently off the charts."

This is the largest Series D in autonomous RCM to date. It won't be the last.

What Candid Actually Does

The pitch is simple. Every insurer runs its own rulebook — more than 1,000 payers, each with its own claim submission quirks, required fields, formatting expectations, and denial triggers. Most providers are still navigating this with billing software built in the early 2000s. When something's off — a misplaced modifier, the wrong code, a payer-specific field out of sequence — the claim bounces. The provider either fights it or eats it.

Candid replaces that process with AI agents and a rules engine trained on the submission requirements of 1,000+ payers. Claims go out correctly the first time. No rework queue, no offshore billing staff manually correcting rejections.

The customer proof points Fortune reported are worth noting:

• Talkiatry: 40% reduction in manual billing work, now collecting 98.3% of what payers owe
• Nourish: grew their business without adding billing headcount, auto-processing 96.7% of claims

Those aren't pilot metrics. Those are production numbers from scaled customers.

The Palantir DNA Behind the Product

Cofounders Nick Perry and Doug Proctor met at Palantir — Perry led healthcare, Proctor built defense and intelligence systems. Their frame for RCM is worth understanding: they see billing as fundamentally a data integration problem. Payers have rules. Providers have claims. The gap between them is structured information that doesn't line up. That's exactly the kind of problem Palantir was built to solve, just applied to medical billing instead of intelligence data.

That framing explains the product architecture. Candid isn't a workflow tool layered on top of existing billing software. It's a rules engine that ingests payer-specific requirements at scale and executes submission correctly, autonomously. The intelligence is in the data, not the UI.

"The people who depend on the health system deserve care that is simpler, more human, and easier to navigate." — The mission framing is patient-facing, but the engine is payer-facing. That's the right architecture for a billing problem.

The $280 Billion Problem They're Targeting

The US spends approximately $280 billion annually on healthcare billing administration. That number — cited consistently across independent sources including federal CMS data — is roughly 1% of GDP. It's almost entirely manual labor: billers, coders, denial management staff, AR follow-up teams, offshore processing operations.

Proctor's stated mission is to shrink the billing industry itself. Not to make it more efficient — to make a large portion of it unnecessary. The labor that props up legacy RCM vendors is the target. The savings, in Candid's model, stay with the provider instead of getting absorbed by a BPO margin layer.

That's a direct threat to every outsourced RCM company selling headcount-based services. And it's why this round is being watched closely across the industry.

Why This Round Signals a Market Inflection

Candid has grown almost entirely by word of mouth — Perry says they spent virtually nothing on marketing until now. The Series D changes that. Sixth Street's check size and Candid's stated plan to use the capital to scale means the growth-by-word-of-mouth phase is ending. Expect a more aggressive go-to-market, more enterprise sales motion, and broader payer coverage.

The growth trajectory also tells you something about where the market is heading. Candid went 6x, then 5x, then 2.5x on a run rate basis in successive years. That's deceleration in percentage terms, but acceleration in absolute dollars — the classic S-curve pattern for a product that's found real product-market fit and is now scaling into a large market.

For context on the competitive landscape: Waystar — which just earned a KLAS "A" rating for RCM suites — processes $2.4 trillion in annual gross claims across 30,000+ clients. Candid is a fraction of that size today. But Candid's growth rate and retention metrics put it on a trajectory that established vendors should be modeling.

What RCM Teams Should Take From This

Three things to watch:

• Payer coverage depth. A rules engine trained on 1,000+ payers sounds comprehensive, but the tail matters. Where does Candid's accuracy degrade — Medicare Advantage plans, regional Blues, smaller regional payors? That's the pressure test for any autonomous billing claim.
• Specialty fit. Talkiatry is behavioral health. Nourish is nutrition/dietetics. Both are high-volume, relatively standardized billing environments. Does the model hold in high-complexity specialties — orthopedics, oncology, hospital-based billing with DRG complexity? The Series D likely funds that expansion.
• Integration surface. Candid needs to connect to EHRs, practice management systems, and clearinghouses to ingest clean claim data. The quality of those integrations determines whether the 96%+ first-pass rate holds at your shop or degrades due to data quality issues upstream.

If you're a revenue cycle director evaluating autonomous billing vendors, Candid is now well-capitalized enough to be a serious enterprise consideration — not just a startup pilot. The funding validates the thesis. The customer metrics validate the product. The question is fit for your specific billing environment.

The Bottom Line

$120M at 3x valuation, 190% ARR growth, 200% net revenue retention. Those numbers don't happen without a product that works. Candid Health just became the best-capitalized pure-play autonomous RCM company in the market.

The $280 billion billing administration market is the target. Legacy BPO vendors running offshore labor models are the incumbents at risk. And the capital is now in place to accelerate.

This is the round that puts autonomous RCM on every CFO's agenda — not as a future-state concept, but as a current-cycle procurement question.